Gene overexpression may protect against Alzheimer’s disease: study Scientists at the University of Colorado Anschutz Medical Campus have discovered the overexpression of a gene tied to cell division and the structure and function of neurons may prevent and protect against cognitive decline in both mice and humans with Alzheimer’s disease.Read More
Induced pluripotent stem cell technology offers potential treatment for hair loss Science Advisory Board spoke with Stemson Therapeutics co-founder and CEO Geoff Hamilton earlier this month at the 2022 Cell & Gene Meeting on the Mesa about the preclinical stage cell therapy company's focus on curing hair loss by leveraging the regenerative power of induced pluripotent stem cells.Read More
Cell therapy startup NKILT Therapeutics takes novel approach to targeting leukemia Biotech startup NKILT Therapeutics is developing a novel approach of engineering natural killer cells to directly target leukemias and solid tumors. Science Advisory Board spoke with Raphaël Ognar, co-founder and CEO of the company earlier this month at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA.Read More
Antion Biosciences takes allogeneic approach to therapies with microRNA technology Science Advisory Board spoke with Dr. Sven Kili, CEO of Antion Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa, where he laid out his vision for where the company is heading and what the industry needs to do to cure diseases with significant unmet medical needs.Read More
CDMO Lonza continues drive to support cell and gene therapy commercial customers In an interview with Science Advisory Board, Alberto Santagostino, senior vice president and head of cell and gene technologies at Swiss contract development and manufacturing organization (CDMO) Lonza, discussed bluebird bio's two recent U.S. Food and Drug Administration-approved gene therapies.Read More
Platform enables precise, efficient delivery of genetic medicines in vivo Biotech company Homology Medicines is leveraging 15 human hematopoietic stem cell-derived adeno-associated virus vectors to precisely and efficiently deliver genetic medicines in vivo via gene therapy or nuclease-free gene editing modality. CEO Albert Seymour spoke with Science Advisory Board about their platform.Read More